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Abstract The purpose of this investigation was to char-
acterize a new mutation in the LDL-receptor (LDLR) gene
in three families with clinically diagnosed familial hyper-
cholesterolemia (FH) from the South-Eastern part of
Poland. Mutational screening with exon by exon sequenc-
ing analysis was performed in all probands. The novel
mutation c986G[T (Cys308Phe) in the exon 7 of LDLR
gene was found in three apparently unrelated probands
with FH. Analysis of the receptor activity of peripheral
blood lymphocytes by binding and uptake of DiL-LDL
showed a signiﬁcant reduction (by 24% versus healthy
control) of the ﬂuorescent label in the lymphocytes of
patients heterozygous for this mutation. Concentrations of
serum LDL-C in probands before treatment were between
9.5 and 10.5 mmol/l. All patients had corneal arcus and
tendon xanthoma. Clinically, families were characterized
by premature coronary artery disease. This mutation
occurred relatively frequently in our group of patients with
FH, but this could be explained by a founder effect since
we demonstrated their common ancestors.
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Introduction
Familial hypercholesterolemia (FH) is an autosomal dom-
inant disorder, which affects approximately 1/500 indi-
viduals worldwide. Familial hypercholesterolemia is
clinically characterized by elevations in low density lipo-
protein cholesterol (LDL-C), tendon xanthoma, and pre-
mature coronary artery disease (CAD). The mortality rate
of FH patients is signiﬁcantly greater than in healthy sub-
jects and several studies have shown, that lipid-lowering
treatment with statins reduces coronary heart disease
mortality [1–3]. Phenotypic expression of mutations in the
LDL-receptor (LDLR) gene varies regarding severity of
impairment of LDLR function, depending on class of
mutation and also on some not fully elucidated environ-
mental and genetic risk factors. Early identiﬁcation and
treatment of FH patients, especially with familial history of
premature atherosclerosis and coronary heart disease, is of
importance in prevention of development of premature
CAD. Several data indicate that an unequivocal diagnosis
of familial hypercholesterolemia, now termed autosomal
dominant hypercholesterolemia, can be obtained only by
identiﬁcation of a mutation in LDLR gene, or APOB or
PCSK9 genes. In this report we described a new mutation
in LDLR gene reoccurring in families with severe risk of
premature CAD, recruited from outpatient lipid clinic from
South-Eastern part of Poland.
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Material included three probands from apparently unre-
lated families, in whom a novel LDLR mutation was found.
These subjects were recruited from 41 families fulﬁlling
criteria of FH. Enrollment criteria for the patients’ genetic
screening based on Simon Broome register [4]. We inclu-
ded patients with deﬁnite as well as with possible FH.
Secondary hypercholesterolemia, such as hypothyroidism,
diabetes and renal or hepatic disease, were excluded by labo-
ratory tests. Subjects were examined for standard cardiovas-
cular risk factors. Xanthomaswere considered to be present if
tendons appeared diffusely enlarged or had focal nodularities.
Serum lipids were determined by enzymatic methods
using Roche reagents, apolipoproteins (apo) A1 and B were
measured by immunoturbidimetric methods.
In all probands exon by exon sequence analysis was per-
formed using direct sequencing of PCR products obtained
with primers pairs published by Amsellen et al. [5]( B i g D y e
3.1 chemistry; ABI 3500 Genetic Analyser, Applied Biosys-
tems—Life Technologies, Carlsbad, CA). In members of the
probands’ families we performed a conventional targeted
PCR-RFLP analysis to detect the presence of the above
described mutation. Ampliﬁcation primers were: 50-GCA
GGGACCAACGAATGCT-30 and50-CCTTCCTCACAC
TGG CAC TTG TA-30. The product had 952 bp and was
digested with BseMI (Fermentas, USA) restriction endonu-
clease into fragments of 505, 390 and 57 bp for the wild type
329C allele or 562 and 390 bp for the mutated 329F allele.
Thus, transversion of cysteine codon TGC to phenylalanine
TTC codon by the end of exon 7 was detected.
In three subjects carrying the novel mutation in LDLR
gene we performed analysis of the LDLR activity using
peripheral blood lymphocytes measurements of binding
and uptake of DiL-LDL [6].
Peripheral blood lymphocytes were isolated from hep-
arinized blood by Histopaque gradient centrifugation. The
cells were incubated in RPMI medium at the density 10
5 in
0.15 ml. Binding of LDLR was tested by incubation on ice
with 5 to 20 lM labeled LDL (BODIPY FL LDL,
Molecular Probes, Eugene, OR) during 1 h. Incorporation
of labeled LDL was tested by incubation in a serum free
RPMI medium or the medium with 5% fetal calf serum
(FCS, Sigma-Aldrich, St. Louis, MO) at 37C during 2 h.
Lymphocytes were analyzed by ﬂow cytometry following
additional labeling of the cells using anti-CD3-PerCP
antibody (Becton–Dickinson, Franklin Lakes, NJ). Binding
of labeled LDL was calculated as an increase of BODIPY
ﬂuorescence in CD3-PerCP gated cells over the control
ones incubated without the labeled LDL. Similarly, incor-
poration of LDL was expressed as the ratio of ﬂuorescence
over the control incubation without labeled LDL. All
experiments were done in triplicates [6–8].
Presence of atherosclerosis was ascertained by mea-
surements of carotid intima media thickness and carotid-
femoral pulse wave velocity, using Complior system.
Intima-media thickness (IMT) was measured on both
proximal and distal wall of the common carotid artery
segments, on the left and right sides, 2 cm below the car-
otid bifurcations. Three measurements at each point were
performed using non invasive two dimensional ultrasound
with Ultrasonograf GE VIVID 7. We analyzed means and
maximal IMT values. The coefﬁcient of variation of IMT
measurement was 5%.
Carotid-femoral pulse wave velocity was measured
using Complior device. Mean of the 10 measurements was
calculated. Coefﬁcient of variation was below 5%.
Results
Clinical and biochemical characteristics of probands and
examined family members who were heterozygous for the
new mutation are presented in Table 1. Pedigrees of the
families are presented in Fig. 1. The probands were female
born in 1977 (No 62.1), female born in 1969 (No 84.1) and
male born in 1974 (No 3.1). They did not smoke, had
normal blood pressure and did not practice any kind of
regular sport activities. They have a strong family history
of premature CAD, all males with high cholesterol died
early because of CAD. Patient’s 3.1 father, had two myo-
cardial infarctions (MIs) at the age of 40 and 50 years.
Father of patient 62.1, and his two brothers, had MIs also at
their forties and underwent coronary by-pass surgery by the
age of 50 years. Their sister, however, age 63, also with
high cholesterol and conﬁrmed LDLR mutation, had no MI
until the time of examination. When extended pedigrees
were collected, she turned out to be mother of patient 84.1.
All male relatives, who deceased prematurely from
CVD, were heavy smokers, until the time of CVD events.
Atherosclerosis, assessed by IMT and PWV measurements,
showed higher values in male proband than in persons
without mutation, matched by age and sex.
Tendon xanthomas were present in all probands. All
patients with mutation had high LDL-C levels, and patient
3.1 had also elevated triglyceride concentration in serum.
All FH patients available for lipid examination had normal
HDL-C level with exception of father of patient 3, who
also had type 2 diabetes.
A novel missense mutation (c986G[T, p C308F or
C329F including the leader peptide of the receptor) in exon
7 of the LDLR gene was found in all three probands, of
whom two turned out related to each other. Using multiple
PCR-based ligation assay (MLPA) copy number abnor-
malities in LDLR gene were excluded in these subjects.
Figure 2 shows results of DNA sequence analysis of exon 7
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123of LDLR gene in probands heterozygous for the novel
mutation. On further targeted screening of their family
members we veriﬁed that this mutation co-segregated with
hypercholesterolemia (Fig. 3). Sister (84.3) and mother
(84.4) of patient 84.1 had also high cholesterol levels and
were heterozygous carriers of this mutation. The daughter
(29.1) of the oldest brother of patient 84.4 also had very
high LDL-C concentration and was a carrier of above
mutation.
The results of the functional analysis of the LDLR
activity of peripheral blood lymphocytes, evaluating their
binding and uptake capacities for DiL-LDL in patients
carrying this mutation are presented on Fig. 4. The ﬁgure
shows mean values of binding and incorporation of the
ﬂuorescently labeled LDL in three patients heterozygous
for c986G[T mutation in comparison to three matched
healthy persons. We observed signiﬁcantly lower inter-
nalization (P\0.01) in the presence of RPMI medium at
the lower concentration of LDL (5 mM/l). In the presence
of FCS fortiﬁed medium internalization was also lower;
however this effect did not reach statistical signiﬁcance.
Analysis of LDLR function in patient 62.1, c986G[T
heterozygote, who did not received hypolipidemic treat-
ment because of her pregnancy revealed also reduced
binding in addition to lower internalization activity (by 23
and 22% respectively) in comparison to three healthy
controls. This ﬁnding further conﬁrms that the mutation has
a functional consequence on LDL clearance and is the
cause of the FH phenotype. However, in patient (3.1),
carrying this mutation and treated with statin during last
two years, plasma lipid concentrations normalized, and his
Dil-LDL binding as well as incorporation were similar to
healthy control. In father of patient 3.1 (with type 2 diabetes
and thyroid disease; TSH-7,62 lIU/ml, fT4-12,1 ng/l) and
with high plasma LDL-cholesterol level despite treatment,
binding and incorporation were markedly lower: binding by
10 and 29%, internalization by 36 and 23% at LDL con-
centration equaled 5 and 20 mM/l, respectively.
A prediction of molecular consequence of the mutation
using Polyphen program conﬁrmed that this missense muta-
tion, locatedin the highlyconserved region ofLDLR gene, is
damaging. Replacement of cysteine by phenylalanine results
inabreakdownofdisulﬁdebondattheextracellulardomainof
LDLR gene, corresponding to the ligand binding site.
Discussion
In this study we described a novel missense mutation
c986G[T in exon 7 of LDLR gene. There are several lines
of evidence, that mutation of LDLR
308Cys is functionally
relevant. First, the mutation showed a clear linkage with
hypercholesterolemia trait within families. Sequencing of
all exons, promoter and introns did not reveal any other
Table 1 Characteristics of the studied families with the novel pC308F mutation of exon 7 of LDLR gene
Parameter Patient 3.1
(male)
Patient 3.4
(father)
Patient 62.1
(female)
Patient 29.1
(female)
Patient 84.1
(female)
Patient
84.2
(son)
Patient 84.3
(sister)
Patient 84.4
(mother)
Age, years 33 61 32 40 41 16 43 68
SBP/DBP, mmHg 140/90 140/90 110/70 125/70 110/65 115/70 110/85 144/78
BMI, kg/m
2 28.5 32.2 23.3 22.6 19.1 21.1 21.6 28.9
WHR 0.75 1.07 0.70 0.83 0.66 0.85 0.71 0.84
Cholesterol,
mmol/l
10.1 7.39 12.67 8.82 7.32 7.38 5.23 6.54
LDL-C, mmol/l 8.1 5.2 10.86 7.0 5.4 5.89 3.74 4.69
Cholesterol,
maximal.values,
mmol/l
11.0 12.0 12.0 11.6 10.0 10.0 8.6 9.3
Apo B, mg/dl 145 nd 148.1 150.2 70.8 90.4 94.1 92.6
Apo A1, mg/dl 194.3 nd 168.2 179.9 164.5 118 136.5 136.9
IMT, mm (mean/
max)
0.9/1.04 nd 0.7/0.8 0.4/0.5 0.5/0.6 nd nd
PWV, m/sec 8.76 nd 7.71 9.15 9.54 nd nd
Corneal arcus Present Present Present Present Absent Present
Tendon xanthoma Present Present Present Present Present Absent Present Present
Treatment Simvastatin
20 mg
Atorvastatn
40 mg,L-thyroxin,
Sulphonylurea
Diet only
(pregnant)
Atorvastatin
40 mg
daily
Simvastatin
40 mg
– Atorvastatin
40 mg
Atorvastatin
40 mg
Nd not done
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123mutations in the LDL-receptor gene. In addition, functional
studies of LDLR activity of peripheral blood lymphocytes
using binding and uptake of DiL-LDL showed signiﬁcant
reduction of ﬂuorescent label in the cells, in comparison to
healthy control. Interestingly, this reduction was observed
only with lower concentrations of LDL, but not with higher
levels of LDL. However, it is in agreement with data,
showing that lower concentrations of LDL in medium
might stronger stimulate LDLR activity [7, 9]. Relatively
low decrease of binding and internalization could result
from the fact, that examined probands were heterozygotes
and 50% of receptors retained functional activity. In other
studies, products of gene with c986G[A( C
308Y) mutation
yielded 31% of LDLR activity in transfected COS cells
[10], what is in line with our results. Several studies have
indicated that human peripheral blood lymphocytes can
(premature
CAD)
?
(premature
CAD, MI,
smoker)
?
62.2:
(premature
CAD,
MI,
smoker)
(premature
CAD, MI,
smoker)
?
84.4: # C-6.54;
HDL-1.3;
LDL-4.7; TG-1.2
29.1: # C-8.8;
HDL-1.1;
LDL-7.0; TG-1.5
62.1: C-12.7;
HDL-1.4;
LDL-10.9; TG-0.9
84.1: # C-7.3;
HDL-1.18;
LDL-3.74; TG-0.45
84.3: # C-5.23;
HDL-1.18;
LDL-3.74;TG-0.45
84.2:
C-7.4;
HDL-1.1;
LDL-5.9;
TG-0.9
3.4: # C-7.4;
HDL-0.9;
LDL-5.2; TG-2.54
3.1: # C-10.1;
HDL-1.0;
LDL-8.1; TG-2.3
Fig. 1 Pedigree of the probands’ families. Family members hetero-
zygous for c986G[T mutation are indicated with ﬁlled circles.
Detailed pedigree examination revealed that mother of patient 84.1
and father of patient 62.1 were siblings, and daughter (29.1) of
another brother of patient 84.4 was also a carrier of this mutation.
Patients without numbers were not available for DNA analysis.
? = FH diagnosis based on clinical data, CAD coronary artery
disease, MI myocardial infarction, C cholesterol, HDL HDL-choles-
terol, LDL LDL-cholesterol, TG triglycerides, # treated with statin
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123mirror LDLR activity of hepatocytes and also of other body
cells, so measurement of LDLR activity of lymphocytes by
ﬂuorescence ﬂow cytometry may be used as a surrogate for
hepatic LDLR activity in vivo. The LDLR activity mea-
surement in patients treated with statin shows, that statin
therapy increases LDLR activity in carriers of this muta-
tion. This was a possible confounder in the assay in patients
from the family number three, especially patient 3.4 who
also had type 2 diabetes, similarly his high plasma tri-
glyceride levels could decrease the size of LDL, thus affect
binding afﬁnity [11].
Furthermore, other missense mutation located at the
same
308Cys codon of exon 7 (C
308G, C
308Y) are reported
to be associated with FH [5, 12–15].
Eventually, the mutation located at the receptor domain
responsible for the ligand binding was predicted to be
damaging, when tested by PolyPhen program.
All probands carrying this mutation were characterized
by very high levels of LDL-C, however in the male proband
from the family three elevated triglyceride levels were also
observed. Similar lipid proﬁle was found in his father, who
also presented type 2 diabetes. There is increasing number of
data, that also patients with phenotype typical for familial
combined hyperlipidemia (with high triglyceride levels),
especially with markedly increased LDL-C and apo B serum
concentration might have mutation in LDLR gene [16].
Families with this mutation had also typical features of
severe FH: corneal arcus, tendon xanthoma and premature
CAD, affecting males even before the age of 50 years.
The novel mutation c986G[T mutation was located in a
highly conserved residues of the epidermal growth factor
(EGF)—precursor homology domain of the LDLR gene.
Other mutations of this codon (C
308G, C
308Y) were
described in families of Ashkenazi Jews, and of Canadian,
Russian, or Flemish origin. In the study of Amsellem et al.,
including patients residing in France for at least three
Fig. 2 DNA sequence analysis showing mutation in exon 7 of LDLR
gene
Fig.3 PCR-RFLP of family 3, conﬁrming co-segregation of mutation
with FH features. Mother (3.3) and son (3.2) of patient 3.1, both with
normal blood lipids, were negative for c986 G[T mutation in LDLR
gene (healthy controls, HC). PCR of DNA of patient 62.1 also shows
presence of mutation. MWM, molecular weight marker (PBR322/
AluI). Fragment lengths in base pairs
Binding RPMI FCS
0
50
100
150 C329F 5
Control 5
C329F 20
Control 20
Incorporation
M
F
I
 
[
R
F
U
]
**
Fig. 4 Characterization of LDLR binding and internalization func-
tions of peripheral blood monocytes using ﬂow cytometric measure-
ments. Mean ﬂuorescence intensity of peripheral blood lymphocytes
in patients with c986G[T mutation and in healthy controls. We
explored LDLR expression in three patients: 3.1, 3.4 and 62.1 and 3
healthy controls. ** denotes p\0.01
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123generations, mutation C
308G caused by T[G transversion
at c985 nucleotide of exon 7 was described [5]. Zakharova
et al. described C
308Y mutation caused by c985G[A
transition in two families from population of St.-Peters-
burg, Russia. In her study, patients with this mutation were
characterized by a similar lipid proﬁle to ours, with very
high LDL-C cholesterol concentration, corneal arcus, ten-
don xanthomas and CAD [4]. Mutation at the same
nucleotide position as we describe occurred also in Chinese
population (C
308Y, c986G[A) (12) and in the Netherlands
[15]. This was classiﬁed as class 2B mutation. Reshef et al.
found in one family originated from Poland (Ashkenazi
Jews) mutation C
308G in LDLR gene [12].
Interestingly, in our population of FH patients this
mutation occurred in four out of 14 patients with conﬁrmed
LDLR mutation among 41 screened subjects with clinical
diagnosis of FH.
In a recent study on molecular pattern of LDLR gene
mutation in Poland only one mutation in exon 7 was found
[17]. The molecular background of FH in Poland is not
clearly deﬁned. Available data include persons living in the
central part of Poland and the recruitment scheme of these
studies could be biased toward severe manifestation [17].
South-Eastern part of Poland, which Krako ´w is the main
city, has not been screened for familial hypecholesterol-
emia yet.
In summary we described clinical and molecular char-
acteristic of a novel mutation in exon 7 from Krako ´w
province family.
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